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Cisplatin is a widely used chemotherapeutic drug that has served as
the basis for development of subsequent generations of platinum-
coordination compounds. Its mechanism of cytotoxicity is the
formation of a variety of DNA adducts of which the covalent 1,2
intrastrand cross-link between two adjacent guanines is the most
abundant (reviewed in Zamble and Lippard, 1995). Acquired resis-
tance to cisplatin occurs frequently during treatment and is impor-
tant due to the narrow therapeutic index of this drug. Small changes
in sensitivity, in the range of twofold, are sufficient to account for
the failure of treatment (Andrews et al, 1990; Fink et al, 1997).
The proteins involved in DNA mismatch repair (MMR) are
evolutionarily conserved. The MMR system detects and repairs
frameshifts, replication errors, mainly base mismatches, and
regulates recombination events (Kolodner, 1995). Interestingly,
the MMR system is also involved in the detection of DNA damage
produced by 6-thioguanine and methylating agents, as well as
cisplatin and carboplatin (Kat et al, 1993; Hawn et al, 1995; Aebi
et al, 1996; Drummond et al, 1996; Fink et al, 1996). It has been
known for some time that loss of MMR results in high level resis-
tance to 6-thioguanine and moderate resistance to a variety of
methylating agents, including N-methyl-N¢-nitro-N-nitrosoguani-
dine (MNNG). Recently, we and others have shown that loss of
MMR also results in low-level resistance to cisplatin and carbo-
platin (Aebi et al, 1996; Drummond et al, 1996; Fink et al, 1996).
In the case of cisplatin, it has previously been shown that hMSH2
is a component of the protein complex that binds to DNA-
containing cisplatin adducts (Duckett et al, 1996; Fink et al, 1996;
Mello et al, 1996), and it has been suggested that the MMR
proteins serve as a detector system for the presence of DNA
damage (Hawn et al, 1995; Kat et al, 1993). The repair of
mismatched bases by the MMR system involves incision of the
mismatch-containing strand, either upstream or downstream of the
mismatch, excinuclease-helicase-mediated removal of a portion of
the incised strand creating a gap, and then filling of the gap and
religation by DNA polymerase and ligase (reviewed in Kolodner,
1995). Many of these steps are similar to those performed by the
nucleotide excision repair system, a DNA repair system that is
known to remove cisplatin adducts from DNA (Zamble and
Lippard, 1995).
We sought to determine whether the MMR system is involved in
the removal of cisplatin adducts from DNA by comparing the
ability of MMR-proficient and -deficient cells of the same genetic
background to form and remove adducts in endogenous DNA and
to reactivate expression of the luciferase gene from a transiently
transfected cisplatin-damaged plasmid. We report here that loss of
MMR had no effect on the extent of cisplatin adduct formation or
the kinetics of adduct removal from genomic DNA as measured by
atomic absorption spectroscopy, but that, contrary to expectation,
loss of MMR facilitated the expression of a reporter gene disabled
by treatment with cisplatin.
MATERIALS AND METHODS
Cell lines and chemicals
The cell lines HCT116+ch2 (clone HCT116/2–1) and
HCT116+ch3 (clone HCT116/3–6), derived from the hMLH1-
deficient human colorectal adenocarcinoma cell line HCT116 by
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Sciences III, 1211 Geneva 4, Switzerlandcomplementation with chromosomes 2 and 3, respectively, were
obtained from Drs CR Boland, M Koi and TA Kunkel.
Complementation with chromosome 3 provides a wild-type copy
of hMLH1 that renders the HCT116+ch3 cells MMR-proficient
(Koi et al, 1994). The hMSH2-deficient human endometrial
carcinoma cell line HEC59 and its subline HEC59+ch2 (clone
HEC59/2–4), complemented with chromosome 2, were also
provided by Drs CR Boland, M Koi and TA Kunkel. In the
HEC59+ch2 cells, the chromosome 2 complementation restores
wild-type hMSH2 and MMR function (Umar et al, 1997). The
cells were grown as previously described (Aebi et al, 1996). The
status of expression of hMLH1 and hMSH2 was confirmed by
Western blot. Cisplatin was obtained from Sigma (St Louis, MO,
USA) and dissolved in 0.9% (w/v) saline. Lipofectin was
purchased from Life Technologies (Gaithersburg, MD, USA).
Cellular pharmacology
The effect of MMR on the repair of cisplatin-damaged DNA was
compared using two pairs of cell lines. The HCT116-derived
sublines differed with respect to MMR activity due to the loss of
hMLH1 function, and the HEC59 cells due to the loss of hMSH2
function. The HCT116 cells contain a hemizygous mutation in
hMLH1 resulting in a truncated, non-functional protein (Boyer et
al, 1995; Carethers et al, 1996). Thus far, complementation of
hMLH1 and hMSH2 defects by expression of these genes from a
vector has not been reported by any laboratory; however,
successful complementation has been achieved using whole chro-
mosomes. The HCT116+ch3 subline is MMR-proficient due to
complementation with a wild-type copy of hMLH1 on chromo-
some 3; the HCT116+ch2 subline is complemented with chromo-
some 2 and is MMR-deficient (Koi et al, 1994; Carethers et al,
1996). Similarly, the HEC59 cells are mutated at different loci on
both alleles of hMSH2 and are deficient in MMR activity (Boyer
et al, 1995); the HEC59+ch2 subline complemented with a wild-
type copy of hMSH2 on chromosome 2 is MMR-proficient (Umar
et al, 1997). The MMR-deficient HCT116 cells are 2.1-fold
resistant to cisplatin when compared to the MMR-proficient
HCT116+ch3 cells in clonogenic assays, and the MMR-deficient
HEC59 cells are 1.8-fold more resistant to cisplatin than the
MMR-proficient HEC59+ch2 cells (Fink et al, 1996). The comple-
mented cells grown in G418 have remained stable for more than 2
years in culture, and repeat clonogenic assays confirmed these
differences in cisplatin sensitivity (data not shown).
Assay of platinum adducts in DNA
The extent of DNA platination was measured by exposing expo-
nentially growing cells for 1 h to 100 mM cisplatin; the cells were
then washed with cold phosphate-buffered saline (PBS) and lysed
in a buffer containing 1% sodium dodecyl sulphate (SDS), 2.6 M
sodium chloride, 0.3 M EDTA pH 8.0. DNA was isolated by
phenol–chloroform extraction and dissolved in buffer containing
10 mM Tris and 1 mM EDTA pH 8.0. Aliquots of the DNA were
digested in 1 M hydrochloric acid at 75°C for 2 h and the
hydrolysate was used for the quantitation of platinum (Pt) by
flameless atomic absorption spectrophotometry (Perkin-Elmer
Model 2380). The rate of cisplatin adduct removal was measured
in cells that were exposed for 1 h to 40 and 80 mM cisplatin and
harvested 0, 6, 20 and 28 h after the end of exposure. The Pt
content of the DNA was measured by atomic absorption spec-
troscopy as described above.
Plasmid reactivation assay
A plasmid carrying a 2.4 kb fragment from pB/LUC that included
the 1.6-kb firefly luciferase cDNA was prepared by ligating a
SalI/NotI fragment that contained the luciferase coding region into
the 6.9-kb mammalian expression vector pKEX-2-XR (Rittner et
al, 1991) placing the luciferase expression under control of the
cytomegalovirus (CMV) promoter. One to 4 mg of plasmid DNA
was dissolved in buffer containing 10 mM Tris and 1 mM EDTA
pH 7.4 and incubated with 5 mM cisplatin at 37°C for 3 h. The
platinated DNA was then purified by ethanol precipitation and
unreacted drug was removed by passage of the DNA through a
G50 Sephadex column. This procedure resulted in plasmid DNA
that was > 90% supercoiled as verified by gel electrophoresis. The
platination procedure yielded 1.5 ± 1.4 pg mg–1 DNA which is
equivalent to 9.3 adducts per plasmid or 3.2 adducts per Luc
coding region and promoter. Similar levels of platination have
previously been shown not to affect the efficiency of transfection
(Eastman and Schulte, 1988).
Equal number of cells (i.e. 200 000 per well) were transfected in
serum-free medium with 1 mg platinated or unplatinated pKEX-2-
XR-Luc in combination with 5 ml lipofectin for a period of 5 h.
Intra-assay variability was minimized by using one lipofectin
mixture for all samples in each experiment. Subsequently, the
DNA was washed off and fresh medium was added. At various
time points after transfection, triplicate samples were washed with
ice-cold PBS and then lysed in a solution containing 1% Triton
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Table 1 Platinum content of genomic DNA as a function of time after cisplatin exposure
40 mM cisplatin 80 mM cisplatin
Time (h) HCT116 +ch2 +ch3 HCT116 +ch2 +ch3
0 100 100 100 100 100 100
6 12.0 ± 3.5 12.1 ± 3.6 10.5 ± 2.7 13.1 ± 2.7 12.2 ± 2.1 11.3 ± 3.3
20 6.4 ± 2.8 4.3 ± 1.7 5.3 ± 1.8 7.2 ± 3.0 6.8 ± 2.2 6.6 ± 2.0
28 1.1 ± 0.3 1.2 ± 0.2 0.9 ± 0.3 1.6 ± 0.5 1.8 ± 0.7 1.7 ± 1.3
The rates of platinum removal were determined in HCT116 sublines at 0, 6, 20 and 28 h after the end of 1 h exposure to 40 and 80 mM
cisplatin. Initial adduct levels were the same in all HCT116 sublines, i.e. 384 fmol mg–1 DNA and 650 fmol mg–1 DNA following exposure to
40 mM and 80 mM cisplatin respectively. Values represent mean ± s.d. (n = 3) per cent of the initial content at the end of the 1 h treatment
with cisplatin. There was no significant difference between MMR-proficient and -deficient cells in the rate of platinum removal over time.X-100, 15 mM MgSO4, 4 mM EGTA, 1 mM dithiothreitol, and
25 mM glycylglycine at pH 7.8 for 10 min. After centrifugation for
5 minutes at 16 000 g, aliquots of the cleared lysate were assayed
for luciferase activity as previously described (Brasier et al, 1989).
The generation of luciferase activity as a function of time was
compared for cells transfected with the unplatinated versus plati-
nated vector (Eastman and Schulte, 1988). To control for variation
in transfection efficiency between experiments, luciferase activity
was expressed as percent of maximum activity attained in each
experiment. In each cell line, the area under the curve of luciferase
activity versus time was computed up to the time of maximal
activity which was 36 and 20 h for HCT116 and HEC59 cells
respectively. The efficiency of plasmid reactivation was calculated
as the ratio of the area under the curve of the platinated vector to
the area under the curve of the unplatinated plasmid.
RESULTS
Effect of MMR on platinum adduct formation and
removal
We have previously shown that after a 1 h incubation in 100 mM
cisplatin the HCT116+ch2 and HCT116+ch3 cells do not differ
significantly in their total cellular uptake of Pt with accumulation
being 303 ± 58 (s.d.) fmol mg–1 protein and 289 ± 82 (s.d.) fmol
mg–1 protein in the two cell lines respectively (P = 0.75, two-tailed
t-test, n = 4) (Aebi et al, 1997). Thus, resistance to cisplatin in the
HCT116+ch2 cells is not due to reduced drug uptake. Likewise,
the extent of DNA platination was similar in the two cell lines
(Aebi et al, 1997).
In order to determine whether loss of MMR altered the kinetics
of adduct removal from the whole genome, the Pt removal rates
were measured in the HCT116 cell lines at 0, 6, 20 and 28 h after
the end of a 1 h exposure to 40 and 80 mM cisplatin. As shown in
Table 1, HCT116 cells and their chromosome-complemented
sublines demonstrated a rapid decrease in adduct content over the
first 6 h following exposure to both cisplatin concentrations, and
the kinetics were similar to those previously reported for cisplatin
adduct removal (Dijt et al, 1988; Eastman and Schulte, 1988;
Jones et al, 1991). However, there was no significant difference
between MMR-proficient and -deficient cells in the rate of
platinum removal over time.
Effect of MMR on plasmid reactivation
The effect of loss of MMR on the function of a gene inactivated by
cisplatin adducts was examined by comparing the ability of MMR-
proficient and -deficient cells to express luciferase from a plati-
nated plasmid-transfected into the cell. Figure 1 shows that
luciferase activity appeared in both the MMR-proficient and -defi-
cient HCT116 sublines with the same kinetics when they were
transfected with non-platinated vector. Maximum luciferase
activity was reached at 36 and 20 h in HCT116 and HEC59 cells,
respectively. When the platinated vector was transfected into the
MMR-deficient HCT116+ch2 subline, there was little impairment
in the generation of luciferase activity (Figure 1A). However,
when the same platinated vector was transfected into the MMR-
proficient HCT116+ch3 subline, both the rate of appearance of the
luciferase activity and the maximal activity attained over the
whole observation period were reduced (Figure 1B). A similar
pattern was observed in the HEC59 system (Figure 2). The kinetics
of appearance of luciferase activity was the same in the HEC59
and HEC59+ch2 cells in the absence of vector platination.
However, the MMR-proficient HEC59+ch2 cells were less
capable of generating luciferase activity from the platinated vector
than the MMR-deficient HEC59 cells.
Figure 3 shows that the efficiency of reactivation, calculated
from all three sets of experiments as the ratio of the area under the
curve of luciferase activity versus time for the platinated plasmid
divided by that for the unplatinated plasmid in each cell line, was
consistently lower in the MMR-proficient cells than in their
MMR-deficient counterparts in both cell systems. The MMR-
proficient HCT116+ch3 cells were 2.1 ± 0.7-fold (± s.d., n = 3)
less efficient at expressing luciferase from the platinated vector
than their MMR-deficient HCT116+ch2 counterparts (P = 0.0355
by paired t-test for the comparison of MMR-proficient vs
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Figure 1 Luciferase activity as a function of time in HCT116 cells.
Luciferase activity was determined following transfection of pKEX-2-XR-Luc
in MMR-deficient HCT116+ch2 cells (A) and MMR-proficient HCT116+ch3
cells (B). (l), non-platinated vector; (l l), platinated vector. Luciferase activity
is expressed as per cent of maximum luciferase activity generated by the
unplatinated vector at 36 h. Data points represent the mean ± s.e.m. of three
experiments each performed with triplicate transfections for every time point-deficient HCT116 cells). In the HEC59 system, the MMR-pro-
ficient HEC59+ch2 cells were 1.9 ± 0.6-fold (± s.d, n = 3) less
efficient at expressing luciferase activity compared to MMR-
deficient HEC59 cells (P = 0.002 by paired t-test for the
comparison of MMR-proficient vs-deficient HEC59 cells).
DISCUSSION
The mechanism by which loss of MMR causes resistance to
cisplatin is unknown. A current hypothesis is that MMR proteins
serve as a detector for DNA damage caused by cisplatin, as they
do for damage produced by methylating agents or the incorpora-
tion of 6-thioguanine, and that MMR proteins are involved in the
generation of a pro-apoptotic signal since loss of MMR in cancer
cells results in increased resistance to cisplatin (Branch et al, 1993;
Kat et al, 1993; Aebi et al, 1996; Drummond et al, 1996; Fink et al,
1996). It is, however, not known whether simple assembly of part
or all of the MMR protein complex on the platinated DNA is suffi-
cient to generate such a signal or whether the apoptosis is activated
by additional damage done to the DNA resulting from attempts
made by the MMR system to remove the cisplatin adduct. A futile
cycle of excision and resynthesis has been suggested as the basis
for the cytotoxicity of agents such as MNNG and 6-thioguanine
that produce damage recognized by the MMR system (Karran and
Bignami, 1994).
Impaired cellular accumulation of cisplatin is a common
mechanism of resistance in the majority of cell lines selected for
resistance to this drug (Gately and Howell, 1993). However,
MMR-deficient HCT116+ch2 and -proficient HCT116+ch3 cells
accumulated the same amount of Pt and had the same extent of
DNA platination after a 1 h exposure to cisplatin. The fact that the
nucleotide excision repair system proteins can both recognize and
remove cisplatin adducts begs the question of whether the MMR
system is similarly able to remove cisplatin adducts as well as to
detect them. The observation that the kinetics of cisplatin adduct
removal appeared to be equivalent in the MMR-proficient and
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Figure 2 Luciferase activity as a function of time in HEC59 cells. Luciferase
activity was determined following transfection of pKEX-2-XR-Luc in MMR-
deficient HEC59 cells (A) and MMR-proficient HEC59+ch2 cells (B). (l),
non-platinated vector; (l l), platinated vector. Luciferase activity is expressed
as percent of maximum luciferase activity generated by the unplatinated
vector at 20 h. Data points represent the mean ± s.e.m. of three experiments
each performed with triplicate transfections for every time point
Figure 3 Efficiency of the generation of luciferase activity in MMR-deficient
and -proficient cells. The efficiency of plasmid reactivation is expressed as
the ratio of the area under the curve of luciferase activity over time for the
platinated vector divided by the area under the curve for the unplatinated
vector in the same cells. Bars indicate mean ± s.e.m. (n = 3). MMR-proficient
HCT116+ch3 cells were less efficient at expressing luciferase from the
platinated vector compared to MMR-deficient HCT116+ch2 cells (P = 0.0355
by paired t-test). Similarly, MMR-proficient HEC59+ch3 cells were less
efficient at expressing luciferase compared to MMR-deficient HEC59 cells
(P = 0.002 by paired t-test)
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o-deficient HCT116 cells suggests that this is not the case. Thus,
the difference in sensitivity to cisplatin cannot be explained by
differential drug uptake or differential cytosolic detoxification of
cisplatin prior to its reaction with the DNA, and the mechanism of
resistance does not alter the rate of adduct removal from the total
genome. One cannot conclude, however, that the MMR system
plays no role in the actual removal of cisplatin adducts from the
DNA since it has been established that cisplatin adducts are prefer-
entially removed from transcribed genes as compared to the total
genome, and that the coding strand is repaired preferentially
compared to the non-coding strand (Jones et al, 1991; May et al,
1993). Thus, measurement of total genomic platination may miss
important functional differences in the ability of MMR-deficient
and -proficient cells to successfully express genes damaged by
platination, since assays of total genomic platination do not
measure the final completion of the repair process.
The reporter gene reactivation assay has several advantages
over total genome Pt measurement as an assay of overall repair.
First, generation of luciferase activity reflects repair activity
directed to a transcribed gene. Second, the assay measures the
ability of the repair systems to complete all steps in the process
and actually generate a functional protein. Third, the reporter gene
reactivation assay has previously been validated for cisplatin
adduct repair (Sheibani et al, 1989; Jennerwein et al, 1991; Parker
et al, 1991; Ali-Osman et al, 1994). One limitation of this assay
system is that it reflects repair processes occurring in an extrachro-
mosomal segment of DNA rather than in an endogenous gene.
The finding that MMR proficiency resulted in impaired expres-
sion of luciferase from the platinated vector was unexpected. The
fact that the same result was obtained in two independent cell
types, each rendered MMR-deficient by the loss of a different
MMR protein, lends credence to the observation. Several explana-
tions are possible. First, successful binding of the MMR complex
of proteins to the cisplatin adduct may sterically hinder the ability
of nucleotide excision repair proteins to access and process the
lesion, as has previously been suggested (Mello et al, 1996). The
ability of the nucleotide excision repair system to remove cisplatin
adducts has been well-documented, as has the fact that adduct
removal by this system is a major determinant of cellular sensi-
tivity to cisplatin (reviewed in Zamble and Lippard, 1995). Thus,
steric hindrance by the MMR proteins would be expected to slow
repair by the nucleotide excision repair system and reduce genera-
tion of luciferase activity. Such a mechanism has been proposed to
explain the ability of another group of cisplatin adduct-binding
proteins, the HMG proteins, to interfere with adduct repair (Huang
et al, 1994). However, in a recent study, (Mu et al, 1997) reported
that addition of the hMSH2/hMSH6 heterodimer to a cell-free
excision repair system did not impair the ability of the nucleotide
excision repair system to remove cisplatin adducts from DNA. The
assay system utilized by these investigators measured only the
excision nuclease activity in the absence of transcription, and
the possibility of a negative interaction between the MMR and
nucleotide excision repair systems in assays including transcrip-
tion needs further investigation.
A second possibility is that, following recognition, the MMR
system processes the adduct in some way that impairs transcrip-
tion, perhaps by damaging the template strand as has been
suggested for the 6-thioguanine and MNNG adducts (Karran and
Bignami, 1994). The MMR system may incise the strand opposite
the adduct resulting, through the action of an exonuclease, in the
creation of a gap whose filling is blocked by the persistence of the
adduct. Under circumstances where the gapped strand is the
template strand this would be expected to diminish transcription.
Finally, a third possible explanation is that the MMR proteins
normally prevent RNA polymerase II from bypassing the cisplatin
adduct, and that when the MMR system is disabled there is a
higher probability of successful bypass transcription.
Transcriptional bypass of Pt adducts by RNA polymerase II in a
similar reporter plasmid has previously been described, albeit at
low levels for cisplatin (Mello et al, 1995). Interestingly, the
cisplatin-resistant human ovarian carcinoma cells A2780/CP70
have increased DNA replication bypass of cisplatin adducts
compared to the parental A2780 cells (Vaisman et al, 1997), and
they have previously been reported to lack hMLH1 expression and
MMR function (Drummond et al, 1996). Additionally, the
A2780/CP70 cells exhibit increased ability to reactivate a reporter
gene (Parker et al, 1991). Further, defects in hMSH6 are associated
with increased resistance and enhanced replicative bypass of
cisplatin (Vaisman et al, 1998). These findings suggest that the
hMutSa heterodimer consisting of hMSH2 and hMSH6 partici-
pates in the recognition of cisplatin adducts and that the loss of
hMutSa results in resistance to cisplatin by allowing enhanced
replicative bypass of cisplatin adducts. Although transcriptional
bypass is likely to generate mutant transcripts, a significant frac-
tion of these may carry silent mutations that still permit the
synthesis of functional proteins. Thus, successful transcription of
damaged genes could explain the reduced toxicity of cisplatin
adducts in cells lacking MMR.
Independent of the mechanism, it is of interest that the loss of
MMR activity has an effect of similar magnitude on both the effi-
ciency of luciferase expression and the level of cellular resistance
to cisplatin. This is consistent with the hypothesis that the
enhanced reactivation ability observed in the MMR-deficient cells
is mechanistically linked to determinants of cellular resistance.
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